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papillomavirus DNA test had sensitivities of 100% (BestPrep) 
and 95.6% (ThinPrep). Specificities were 71.4% (BestPrep) 
and 54.8% (ThinPrep).  Conclusions: BestPrep was equivalent 
to ThinPrep for manual review even though BestPrep was 
always the second sample collected. The BestCyte cell sorter 
provides a practical alternative to manual review for both 
BestPrep and ThinPrep slides.  © 2014 S. Karger AG, Basel 
 Introduction 
 Liquid-based thin-layer Papanicolaou (Pap) smears 
have become the standard primary preparation for cervi-
cal cytology in most of the developed world replacing 
conventional Pap smears. The two major competitors in 
the liquid-based cervical cytology market, ThinPrep ® 
(Hologic, Bedford, Md., USA) and SurePath (Becton 
Dickinson, Burlington, N.C., USA), offer both automated 
slide preparation and image analysis (automated screen-
ing). Automated screening, as a primary screen or pre-
screen for normal cases, is now accepted in many cytol-
ogy laboratories, with manual follow-up of cases deter-
mined to be abnormal. CellSolutions LLC (Greensboro, 
N.C., USA) is a new entrant into this competition to im-
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 Abstract 
 Objective:  A double-blind study was conducted to compare 
the performance of the new BestPrep ® (CellSolutions) liq-
uid-based thin-layer Papanicolaou (Pap) test with ThinPrep ® 
(Hologic).  Study Design:  Samples from the study patients
(n = 105) were collected twice in the same encounter with 
the ThinPrep sample always taken first and the BestPrep 
sample collected second. Slides were prepared according to 
both manufacturers’ protocols and evaluated using manual 
microscopic review and the BestCyte ® cell sorter imaging 
system (CellSolutions). Diagnostic truth for each case was 
determined by independent manual review of both slides by 
multiple pathologists and histology when available. The 
presence of atypical squamous cells of undetermined sig-
nificance was the threshold for positive for sensitivity and 
specificity calculations.  Results:  BestPrep and ThinPrep, by 
manual review, had sensitivities for high-grade squamous 
intraepithelial lesion (HSIL) cases of 100 and 95.6%, respec-
tively. Using the BestCyte cell sorter, both had 100% sensitiv-
ity. For the same HSIL cases, the  digene HC2 high-risk human 
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prove cytology and is offering an automated liquid-based 
Pap test preparation (BestPrep ® ) and an automated in-
teractive digital slide imaging system (BestCyte ® cell 
sorter) as a primary screening device.
 The BestPrep process starts with the collection of the 
cervical cytology sample using a Rovers brush (Rovers 
Medical Devices B.V., Oss, The Netherlands). The head 
of the collection device is then placed into the BestPrep 
collection vial containing 10 ml of the BestPrep ethanol-
based liquid preservative. The collected specimen is 
transferred to centrifuge tubes, and the cells are concen-
trated by precentrifugation. The cell pellet is resuspended 
based on cellularity determined by the automated mea-
surement of the cell pellet size, and the BestPrep Pap slide 
is then prepared automatically using the BestPrep prepa-
ration device (CS-30 or CS-120). The BestPrep includes 
positive sample identification and barcoding. Staining 
and coverslipping are done independently based on the 
method chosen by the laboratory.
 The BestCyte cell sorter is a very high-speed automated 
digital cytology scanner and imaging software that sorts 
and displays digital images on a high-resolution monitor 
(2,560 × 1,440 pixels;  fig. 1 ). The system scans and saves the 
digital image of the entire cell deposition area and then se-
lects, sorts and presents selected cells and cell clusters in 
galleries based on predefined cytological classifications 
( fig. 2–4 ). In addition to the review of the galleries, the user 
also has the capability to do a full slide review of the virtual 
digital slide image. The two other cytology imaging sys-
tems, BD FocalPoint GS Imaging System and ThinPrep 
Imaging System, relocate 10–22 entire fields of view on a 
microscope (hundreds to thousands of cells) without mark-
ing or presenting specific potentially abnormal cells or 
groups of cells  [1, 2] . With the BestCyte cell sorter, the en-
tire digital slide and selected potentially abnormal cells and 
cell groups are displayed in high resolution for the review-
er. Consequently, the cytologist is given a strong indication 
of the number of abnormal cell types and therefore evi-
dence as to the degree of abnormality. Since saved images 
of the entire cell deposition area are available for review 
with the BestCyte cell sorter, the actual glass slide is not re-
quired in most cases, thus allowing for remote screening 
from any location using a web browser. As with the glass 
slide, the reviewer is able to pan and scan the digital image 
for determination of adequacy and the presence of organ-
isms.
 This study was designed to evaluate the new automated 
liquid-based thin-layer Pap slide preparation BestPrep 
against the ThinPrep Pap test as the predicate method. The 
ThinPrep sample was always collected first in this study. 
The relative sensitivities and specificities of the two liquid-
based thin-layer cytology methods, ThinPrep and Best-
Prep, were compared using both manual screening and 
BestCyte cell sorter imaging review. Using the same patient 
cohort, this study also compared sensitivities and specifici-
ties for the  digene HC2 high-risk human papillomavirus 
(HPV) test (Qiagen, Gaithersburg, Md., USA) between the 
two liquid-preserved samples (ThinPrep and BestPrep).
 Materials and Methods 
 A double-blind, institutional review board-approved study was 
conducted to compare the performance of the new BestPrep (Cell-
Solutions) liquid-based thin-layer Pap test with ThinPrep (Holog-






















   
   
   
   
   
   
   
   
   
   

























ic). The patient cohort in this study included 105 women aged 
21–84 years (mean age: 41 years). Many of the women had been 
referred to colposcopy due to a prior abnormal Pap test or were 
considered to be at high risk for abnormality. Pap tests were per-
formed at two hospitals, the University Hospital of Liège (site
N.-D. des Bruyères) and the Citadelle Regional Hospital, by gyne-
cologists or their professional staff who were trained in the collec-
tion of cervical cytology samples using a Rovers Cervex-Brush ® . 
Although the data presented are based on only 105 paired samples, 
the study cohort provided enriched sampling of abnormal cells due 
to the number of patients with prior clinical diagnoses of abnor-
mality, thus allowing for a smaller sample size in this preliminary 
evaluation.
 In the collection of the samples, two separate Rovers Cervex-
Brushes were used, one for the ThinPrep sample and one for the 
BestPrep sample. In every case, the BestPrep sample was always 
taken second, which usually implies the disadvantage of acquiring 
only residual exfoliated cells and possibly additional blood  [3, 4] . 
This recognized disadvantage in sampling was tolerated to allow 
collection of the ThinPrep sample per current methodology and 
for reporting of patient results per accepted institutional practice. 
In both cases, the manufacturers’ recommendations were followed 
for slide preparation.
 The six cytotechnologists and two cytopathologists who were 
involved in the study were blinded as to patient identity, and slides 
were randomized for review. Study participants did not have ac-
cess to the identification key for the slides. As with routine labora-
tory practice, both slide types (ThinPrep and BestPrep) were ini-
tially screened manually by the cytotechnologists, and all slides 
determined to be abnormal were reevaluated and diagnosed by the 
cytopathologists.
 Following manual evaluation, both slide types (ThinPrep and 
BestPrep) were cleaned of all markings and subsequently micro-
scopically scanned and imaged with the BestCyte cell sorter im-
ager. This imaging device, developed by CellSolutions LLC, auto-
matically scans the entire cell deposition area of the slide ( ≈ 300 
mm 2 or 15 × 20 mm for BestPrep and  ≈ 314 mm 2 or 20 mm in di-
ameter for ThinPrep), using a ×20 objective and a high-resolution 
CCD digital camera. The digital images are saved and simultane-
ously analyzed by the BestCyte classifier software, which has been 
developed to recognize normal and abnormal cells and clusters. 
The software then selects and sorts cells and cell clusters based on 
cell appearance characteristics for display in image galleries. Im-
ages are then reviewed by cytology professionals using the interac-
tive user interface.






















   
   
   
   
   
   
   
   
   
   

























 Fig. 3. Example of cell clusters in gallery on the BestCyte cell sorter.  






















   
   
   
   
   
   
   
   
   
   

























 Unlike the ThinPrep imaging system, which provides 22 se-
lected field-of-view locations for review with the actual glass slide, 
image review with the BestCyte cell sorter is conducted using the 
digital image alone for most cases, without the requirement for the 
actual glass slide to be present during review. Additionally, the 
BestCyte cell sorter imager was designed to facilitate current labo-
ratory practice for manual review by providing the entire slide im-
age as well as selected cells in the image galleries.
 The BestCyte does not automatically annotate cells and cell 
clusters, but it essentially annotates cells and cell clusters by place-
ment in specific galleries based on cell characteristics. In addition, 
there is an annotation tool that allows users to electronically mark 
and specifically annotate cells of interest similar to the practice of 
dotting an actual glass slide. Once annotated, these specific anno-
tations are then available to all follow-on reviewers, including the 
pathologist. However, annotations may be modified at the discre-
tion of a more senior reviewer. For determination of adequacy and 
presence of organisms, selected fields of view are displayed. These 
or the whole slide image allow the reviewer to scan and pan all or 
part of the entire cell deposition area similar to a manual review. 
For case diagnosis, the BestCyte cell sorter provides selections 
from a diagnostic result window that includes all of the Bethesda 
cytology classifications for diagnosis by the primary, quality con-
trol and pathologist reviewers. Image review using the ThinPrep 
Imaging System was not part of this study.
 The dual collection from the same patient into two different 
types of cytological preservatives, gynecological not general 
(GYN) cytology preservative (CellSolutions) and PreservCyt 
(Hologic), afforded the opportunity to do a comparison of HPV 
sensitivity and specificity between the two preservative media 
using residual cell material following slide preparation. For HPV 
testing, the  digene HC2 high-risk HPV DNA test was used ac-
cording to the approved protocol for ThinPrep and a slightly 
modified protocol provided for BestPrep.
 Diagnostic truth for each case (paired ThinPrep and BestPrep 
slides from the same patient) in the study was based upon agree-
ment of diagnostic category (using established Bethesda classifi-
cations) between two cytopathologists. For most of the abnormal 
cases, current histology results were available to support diagnos-
tic truth for the cases. Any new abnormal determination from the 
image review was adjudicated based on the manual review results 
by multiple cytologists reviewing both slides and images as neces-
sary.
 For statistical analysis, the cases were grouped according to 
the determined Bethesda diagnostic truth for each case. Sensitiv-
ity was then calculated for each preparation method (ThinPrep 
vs. BestPrep), and low- (LSIL) and high-grade squamous intraep-
ithelial lesion (HSIL) cases. In like fashion, manual and imaging 
results were compared for the same slides. Likewise, specificity 
was calculated for the two preparation methods and screening 
methods based on the number of true-negative cases and the 
number of false-positive cases for all negative ‘truth’ cases. Sensi-
tivity and specificity for HPV results (positive vs. negative results) 
for specimens collected in the two types of preservative fluid 
(ThinPrep PreservCyt vs. GYN cytology preservative) were also 
calculated.
 Confidence intervals (CI) for estimates of sensitivity and specific-
ity were calculated using the binominal distribution (i.e. they were 
exact CI). All CI provide an estimated interval within which we can 
be 95% confident that the actual sensitivity or specificity occurred.
 Results 
 The overall preparation quality and cell presentation 
were comparable between the ThinPrep and BestPrep 
slides. Specimen adequacy and the recovery of endocer-
vical cells and infectious agents were similar between 
the two preparation methods. There were 7 unsatisfac-
tory ThinPrep slides and 2 unsatisfactory BestPrep 
slides in the manual review arm of the study (statisti-
 Table 1.  ThinPrep manual versus BestPrep manual (HSIL is truth 
for the cases – ASC-US is the threshold for positive)
 BestPrep manual







HSIL 1 2 16 19
UNSAT
Total 1 1 2 19 23
 AGC = Atypical glandular cells of undetermined significance; 
ASC-H = atypical squamous cells: cannot exclude high-grade 
squamous intraepithelial lesions; NILM = negative for intraepithe-
lial lesions or malignancy; UNSAT = unsatisfactory. ThinPrep ma-
nual sensitivity: 95.6% (95% CI = 78.1 – 99.9%). BestPrep manual 
sensitivity: 100% (95% CI = 85.2 – 100%).
 Table 2.  ThinPrep manual versus BestPrep manual (LSIL is truth 
for the cases – ASC-US is the threshold for positive)
 BestPrep manual
NILM ASC-US AGC LSIL ASC-H HSIL UNSAT total
ThinPrep manual
NILM 3 1 1 1 1 7
ASC-US 1 1 2
AGC
LSIL 1 2 12 2 3 20
ASC-H
HSIL 1 1
UNSAT 1 2 2 5
Total 5 6 1 14 5 4 35
 See table 1 for abbreviations. ThinPrep manual sensitivity: 
80.0% (95% CI = 63.1 – 91.6%). BestPrep manual sensitivity: 85.7% 






















   
   
   
   
   
   
   
   
   
   

























cally significant, p = 0.05). In the imaging arm of the 
study, unsatisfactory slide determinations were always 
referred to manual microscopic evaluation along with 
any imaged slide that was selected for manual review by 
either a cytotechnologist or cytopathologist. Selection 
for manual review is done when the result from the im-
age review yields an uncertain diagnostic outcome. In 
this study, there were 9 ThinPrep cases and 7 BestPrep 
cases marked for manual review by one or more of the 
cytologists performing image review. In these cases, the 
manual result was also used for the image-based deter-
mination.
 Sensitivity and specificity calculations for the two 
preparation and screening methods are reported and 
compared in  tables 1–7 grouped according to diagnos-
tic truth using the Bethesda classifications listed. Sensi-
tivity and specificity calculations for the HPV test re-
sults from cytological collections made from ThinPrep 
versus BestPrep preservative fluid are shown in  tables 8 
and  9 .
 Table 3.  BestPrep manual versus BestPrep BestCyte (HSIL is truth 
for the cases – ASC-US is the threshold for positive)
 BestPrep BestCyte






ASC-H 1 1 2
HSIL 3 1 1 14 19
UNSAT
Total 4 1 2 16 23
 See table 1 for abbreviations. BestPrep manual sensitivity: 100% 
(95% CI = 85.2 – 100%). BestPrep BestCyte sensitivity: 100% (95% 
CI = 85.2 – 100%).
 Table 4.  BestPrep manual versus BestPrep BestCyte (LSIL is truth 
for the cases – ASC-US is the threshold for positive)
 BestPrep BestCyte
N ILM ASC-US AGC LSIL ASC-H HSIL UNSAT total
BestPrep manual
NILM 2 3 5
ASC-US 2 2 1 1 6
AGC 1 1
LSIL 1 2 8 3 14
ASC-H 1 3 1 5
HSIL 1 3 4
UNSAT
Total 5 8 13 4 5 35
 See table 1 for abbreviations. BestPrep manual sensitivity: 
85.7% (95% CI = 69.7 – 95.2%). BestPrep BestCyte sensitivity: 
85.7% (95% CI = 69.7 – 95.2%).
 Table 5.  ThinPrep manual versus ThinPrep BestCyte (HSIL is 
truth for the cases – ASC-US is the threshold for positive)
 ThinPrep BestCyte






ASC-H 1 1 2
HSIL 4 1 1 12 1 19
UNSAT
Total 5 2 1 12 3 23
 See table 1 for abbreviations. ThinPrep manual sensitivity: 
95.6% (95% CI = 78.1 – 99.9%). ThinPrep BestCyte sensitivity: 
100% (95% CI = 85.2 – 100%).
 Table 6.  ThinPrep manual versus ThinPrep BestCyte (LSIL is truth 
for the cases – ASC-US is the threshold for positive)
 ThinPrep BestCyte
NI LM ASC-US AGC LSIL ASC-H HSIL UNSAT total
ThinPrep Manual
NILM 5 2 7
ASC-US 2 2
AGC
LSIL 2 2 14 2 20
ASC-H
HSIL 1 1
UNSAT 1 4 5
Total 7 4 14 1 3 6 35
 See table 1 for abbreviations. ThinPrep manual sensitivity: 
80.0% (95% CI = 63.1 – 91.6%). ThinPrep BestCyte sensitivity: 






















   
   
   
   
   
   
   
   
   
   


























 In this study, the predicate method, ThinPrep, always 
had the advantage of being the first sample collected, with 
BestPrep always relegated to the second collection. It is 
widely accepted that the first sample, in situations where 
abnormal cells are scarce, is more likely to contain the 
abnormal material. The second sample has a greater like-
lihood to contain blood, which can obscure cells on the 
preparation. In spite of this disadvantage, the data suggest 
that this had no effect on BestPrep.
 As can be seen in the  tables 1–7 , there is an excellent 
agreement of sensitivities and specificities for both prep-
arations and both methods of analysis when the presence 
of atypical squamous cells of undetermined significance 
(ASC-US) is used as the threshold for positive. Diagnostic 
accuracy as to the specific Bethesda classification is simi-
lar for both study arms with some variation as to specific 
diagnostic interpretation as is typical of cytology diagno-
ses among different preparations and different reviewers. 
Variation in the specific Bethesda diagnosis from the 
‘truth diagnosis’ was greater using the BestCyte. This may 
be expected to improve with better training and more ex-
perience in diagnostic image review ( tables 3–6 ).
 The BestCyte cell sorter timed operator involvement 
with image review for each slide. For the majority of cas-
es, review time was between 0.5 and 3 min per slide. 
Cytotechnol ogists typically screen between 40 and 100 
slides per day – with an average manual review time per 
slide ranging from 5 to 10 min  [5] . When one considers 
that study cytotechnologists had limited experience using 
BestCyte cell sorter, this suggests that much less time may 
be spent using BestCyte image review than with tradi-
tional microscopic screening. Image-based evaluation 
 Table 7.  Specificity for four methods evaluated (negative is truth for these cases – ASC-US is the threshold for 
positive)
ASC-US AGC LSIL ASC-H HSIL Specificity (95% CI)
ThinPrep manual 4 1 88.1% (74.4 – 96.0%)
ThinPrep BestCyte 2 95.2% (83.8 – 99.4%)
BestPrep manual 4 1 88.1% (74.4 – 96.0%)
BestPrep BestCyte 2 1 92.8% (80.5 – 98.5%)
 AGC = Atypical glandular cells of undetermined significance; ASC-H = atypical squamous cells: cannot ex-
clude high-grade squamous intraepithelial lesions. In 42 cases, truth was negative.
 Table 8.  HPV sensitivity for both PreservCyt and CellSolutions GYN cytology preservative for cases that are
ASC-US+ (truth for the cases are shown)
Truth Hologic PreservCyt  CellSolutions preservative
pos. neg. sensitivity (95% CI) p os. neg. sensitivity (95% CI)
HSIL+ 22 1 95.6% (70 – 99.9%) 23 0 100% (85.2 – 100%)
LSIL 30 5 86% (69.7 – 95.2%) 31 4 88.6% (74.8 – 96.4%)
ASC-US 2 2 50.0% (6.8 – 93.2%) 2 2 50.0% (6.8 – 93.2%)
 Table 9.  HPV specificity for both PreservCyt and CellSolutions GYN cytology preservative (42 cases had HPV 
tests with truth for the cases being negative)
Neg. truth cases Neg. HPV test Pos. HPV test Specificity (95% CI)
PreservCyt 42 23 19 54.8% (47.1 – 62.4%)






















   
   
   
   
   
   
   
   
   
   

























may have a varied learning curve impacting users in dif-
ferent ways. Individual performance, such as speed and 
perceived user friendliness, may well depend on personal 
experience with computers, digital pathology and the 
number of years of experience with conventional cytolo-
gy screening.
 HPV results from cytological collections made from 
ThinPrep versus BestPrep preservative fluid are shown in 
 tables 8 and  9 . The HPV test results from GYN cytology 
preservative fluid were slightly more specific and in better 
agreement with cytological evaluation than HPV testing 
from ThinPrep PreservCyt.
 The review of performance of the BestCyte cell sorter 
suggests that the BestCyte offers an efficient way to screen 
slides in that it reduces screening time to less than half of 
the time typically spent screening slides manually. Sensi-
tivities, using ASC-US+ as the diagnostic threshold of 
positive, shows similar sensitivity and specificity to man-
ual microscopic evaluation. This study suggests that the 
BestCyte cell sorter may play a role in improving efficien-
cy and productivity in the evaluation of both ThinPrep 
and BestPrep liquid-based thin-layer slides.
 When ASC-US+ is used as the cutoff for positivity, cy-
tological evaluation by either method (BestPrep or Thin-
Prep) is similar to  digene HC2 high-risk HPV DNA test-
ing as to sensitivity and better than HPV testing relative 
to specificity. This is not a new finding. If one reviews the 
literature, as Nanda et al.  [6] reported in a previous pub-
lication, cytology often performs well in sensitivity and 
specificity in quality laboratories using typical ASC-US 
standards of interpretation with ASC-US as the positive 
cutoff. As an example of achievable cytology sensitivity 
and specificity, Bolick and Hellman  [7]  reported sensitiv-
ity for ThinPrep LSIL+ for cervical intraepithelial neopla-
sia (CIN) 2–3 cases or higher of 94.2% and specificity of 
57.7%  [8] . Zhao et al. [9] reported that verification bias-
adjusted Pap screening sensitivity was 93% in the cytol-
ogy laboratory of Magee-Womens Hospital. In a recent 
publication, Pan et al.  [10] reported sensitivities and spec-
ificities using liquid-based cytology in a very large trial. 
Sensitivity and specificity for cytology was 81 and 95.4% 
for CIN 2+ and 88.5 and 94.3% for CIN 3+. Often when 
cytology is perceived as having lower sensitivity, labora-
tory quality and interpretation strategies should be scru-
tinized (e.g. ASC-US calls may be discouraged, a less-sen-
sitive image-based prescreener may be in use or a higher 
cutoff than ASC-US was used).
 Data generated in this study suggest that both cytology 
and HPV testing can be equivalent as to sensitivity, and 
both therefore may be suitable for prescreening or ‘first-
test’ methods, but it demonstrates that HPV testing alone 
is less specific. Certainly, positive HPV tests should be 
followed by cytology because of the characteristic low 
specificity of HPV. Both tests are complementary, some-
times adding valuable, clarifying data points that may be 
important to consider before referring to colposcopy and 
biopsy. This study suggests reconsideration of screening 
with both methods when the greatest diagnostic sensitiv-
ity and specificity are mandated, and when costs are not 
an issue. Screening sensitivities of HPV testing are not 
always high, as evidenced in the FDA Summary of Safety 
and Effectiveness Data (SSED) for the recent Roche cobas 
HPV test (ATHENA Evaluation; Roche Molecular Sys-
tems, Inc., Pleasanton, Calif., USA) where HPV screening 
sensitivity for all CIN 3+ cases was only 58.26% (95% CI: 
44.02–74.37%) for women  ≥ 25 years (table  39 from 
SSED) and 53.56% (95% CI: 36.79–76.01%) for women 
aged  ≥ 30 (table 40 from SSED)  [11] . Regarding costs, the 
respective costs of either method, cytology or HPV test-
ing, should be a major determinant in cost-restrained 
screening programs. Both prescreening costs, and the 
number and costs of ‘follow-on’ second tests need to be 
carefully determined. New methods that impact costs and 
performance should also be taken into consideration be-
fore making final decisions. Cytology supply pricing is 
adjusting downward as new products offer competitive 
options. HPV test reagents are usually expensive com-
pared to cytology. When HPV alone is performed as the 
primary test, the additional costs of cytology follow-up on 
high numbers of samples and the possibility of an addi-
tional collection is mandated by the poor specificity of 
HPV. If cytology is performed in a quality laboratory with 
similar sensitivities to those of HPV, the cost of a second-
ary test is less frequently required.
 Cytology has, without question, improved women’s 
health and reduced morbidity  [12] . It is the most success-
ful cancer screening test for decades and the standard of 
achievement among all efforts to eradicate high-inci-
dence types of cancer. At this point, cytology, as opposed 
to HPV, has the distinct advantage of suggesting the de-
gree of potential abnormality based upon the level of cel-
lular dysplasia that is visible microscopically. Cytology 
results often directly correlate to histopathology diagno-
ses as both are based on observed morphologic changes 
in cells. Microscopy can also supply other important di-
agnostic information, such as evidence of active infec-
tions involving HPV, trichomonas, candida, herpes, bac-
teria and other infectious agents. These microscopic ob-
servations of active infection are available at no 






















   
   
   
   
   
   
   
   
   
   

























improve academically and commercially over time 
through new technology innovation, including advances 
in preservatives, preparation quality, imaging and mo-
lecular diagnostics. These improved new technologies are 
in various stages of implementation and can be expected 
to improve further as to sensitivities, specificities and pre-
dictive outcomes. Care should be taken to weigh all new 
technology carefully and thoughtfully as to actual quality 
contributions and real cost benefits before altering the 
long-established, proven diagnostic paradigm and the re-
sulting benefits that are correctly attributed to cytology 
and Pap screening.
 This study demonstrated the excellent sensitivity and 
specificity of cytology achievable with both traditional 
microscopic screening and a new approach, involving re-
view of high-resolution digital images selected and sorted 
according to cell characteristics. In this study, cytology-
based sensitivities were as good as those achieved using 
molecular testing for HPV-DNA. Cytology specificity, as 
in most comparisons, was better than that of the HPV-
DNA testing.
 The performance of the new CellSolutions BestPrep was 
equivalent to that of the Hologic ThinPrep for manual 
screening even though BestPrep was always relegated to the 
second sample collection. The BestCyte cell sorter appears 
to be a practical alternative to manual microscopic evalua-
tion of both BestPrep and ThinPrep slide preparations.
 Disclosure Statement 
 CellSolutions and Klinipath supplied reagents, materials and 
financially supported some of the labor involved in the study. Qia-
gen supplied the  digene HC2 high-risk HPV DNA test kits.
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